Gender differences in self-reported symptom awareness and perceived ability to manage therapy with disease-modifying medication among commercially insured multiple sclerosis patients

Journal of Managed Care Pharmacy

Volumn 16, Issue 3, 2010, Pages 206-216

  Vlahiotis, Anna ^a   Sedjo, Rebecca ^a   Cox, Emily R ^a   Burroughs, Thomas E ^b   Rauchway, Amy ^b   Lich, Rebecca ^a  

^a Express Scripts   (United States)

^b SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLATIRAMER; INTERFERON BETA SERINE; MITOXANTRONE; NATALIZUMAB; STEROID; IMMUNOLOGICAL ADJUVANT;

ADULT; ARTICLE; AWARENESS; CONTROLLED STUDY; DEMOGRAPHY; DISEASE COURSE; DISEASE EXACERBATION; EDUCATIONAL STATUS; FEMALE; HEALTH STATUS; HUMAN; INCOME; MAJOR CLINICAL STUDY; MALE; MANAGED CARE; MULTIPLE SCLEROSIS; PATIENT ATTITUDE; PHARMACY; PRESCRIPTION; QUESTIONNAIRE; RELAPSE; SELF REPORT; SEX DIFFERENCE; SYMPTOM; ADOLESCENT; ATTITUDE TO HEALTH; INFORMATION PROCESSING; MIDDLE AGED; MULTIVARIATE ANALYSIS; PATHOPHYSIOLOGY; PATIENT EDUCATION; STATISTICAL MODEL; UNITED STATES;

ADJUVANTS, IMMUNOLOGIC; ADOLESCENT; ADULT; DATA COLLECTION; FEMALE; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; MULTIVARIATE ANALYSIS; PATIENT EDUCATION AS TOPIC; SEX FACTORS; UNITED STATES; YOUNG ADULT;

EID: 77952310554     PISSN: 10834087     EISSN: None     Source Type: Journal    
DOI: 10.18553/jmcp.2010.16.3.206     Document Type: Article

References (48)

1. National Multiple Sclerosis Society. Who gets MS? Available at: http://www1.nationalmssociety.org/about-multiple-sclerosis/what-we-know-about- ms/who-gets-ms/index.aspx. Accessed February 25, 2010.
2. Confavreux C, Vukusic S. Natural history of multiple sclerosis: a unifying concept. Brain. 2006;129(Pt 3):606-616 (Pubitemid 43278223)
3. National Multiple Sclerosis Society. Four disease courses of MS. Available at: http://www.nationalmssociety.org/about-multiple-sclerosis/what-we- know-about-ms/what-is-ms/four-disease-courses-of-MS/index.aspx. Accessed February 25, 2010.
4. Duquette P, Pleines J, Girard M, Charest L, Senecal-Quevillon M, Masse C. The increased susceptibility of women to multiple sclerosis. Can J Neurol Sci. 1992;19(4):466-471
5. Coyle PK. Gender issues. Neurol Clin. 2005;23(1):39-60, v-vi.
6. Voskuhl RR. Gender issues and multiple sclerosis. Curr Neurol Neurosci Rep. 2002;2(3):277-286
7. Trojano M, Pellegrini F, Paolicelli D, et al. Post-marketing of disease-modifying drugs in multiple sclerosis: an exploratory analysis of gender effect in interferon beta treatment. J Neurol Sci. 2009;286(1-2):109-113
8. Goodin DS, Frohman EM, Garmany GP, Jr., et al. Disease-modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Neurology. 2002;58(2):169-178
9. National Clinical Advisory Board of the National Multiple Sclerosis Society. Disease management consensus statement. 2007. Available at: http://www1.nationalmssociety.org/about-multiple-sclerosis/what-we-know-about- ms/treatments/download.aspx?id=8. Accessed February 25, 2010.
10. Leary SM, Thompson AJ. Primary progressive multiple sclerosis: current and future treatment options. CNS Drugs. 2005;19(5):369-376
11. McCormack PL, Scott LJ. Interferon-beta-1b: a review of its use in relapsing-remitting and secondary progressive multiple sclerosis. CNS Drugs. 2004;18(8):521-546
12. Minden S, Hoaglin D, Jureidini S, et al. Disease-modifying agents in the Sonya Slifka Longitudinal Multiple Sclerosis Study. Mult Scler. 2008;14(5):640-655 (Pubitemid 351954407)
13. Langer-Gould A, Moses HH, Murray TJ. Strategies for managing the side effects of treatments for multiple sclerosis. Neurology. 2004;63(11 Suppl 5):S35-41. (Pubitemid 39628573)
14. Brandes DW, Callender T, Lathi E, O'Leary S. A review of disease-modifying therapies for MS: maximizing adherence and minimizing adverse events. Curr Med Res Opin. 2009;25(1):77-92.
15. Whitlock FA, Siskind MM. Depression as a major symptom of multiple sclerosis. J Neurol Neurosurg Psychiatry. 1980;43(10):861-865 (Pubitemid 11250728)
16. Sadovnick AD, Remick RA, Allen J, et al. Depression and multiple sclerosis. Neurology. 1996;46(3):628-632
17. Mohr DC, Goodkin DE, Likosky W, Gatto N, Baumann KA, Rudick RA. Treatment of depression improves adherence to interferon beta-1b therapy for multiple sclerosis. Arch Neurol. 1997;54(5):531-533 (Pubitemid 27204238)
18. Miller A, Dishon S. Health-related quality of life in multiple sclerosis: the impact of disability, gender and employment status. Qual Life Res. 2006;15(2):259-271 (Pubitemid 43230116)
19. Iezzoni LI, Ngo LH, Kinkel RP. Working-age persons with multiple sclerosis and access to disease-modifying medications. Mult Scler. 2008;14(1):112-122
20. Mohr DC, Boudewyn AC, Likosky W, Levine E, Goodkin DE. Injectable medication for the treatment of multiple sclerosis: the influence of self-efficacy expectations and injection anxiety on adherence and ability to self-inject. Ann Behav Med. 2001;23(2):125-132 (Pubitemid 32488430)
21. Gaines AR, Varricchio F. Interferon beta-1b injection site reactions and necroses. Mult Scler. 1998;4(2):70-73. (Pubitemid 28197349)
22. Hartung HP, Gonsette R, Konig N, et al. Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial. Lancet. 2002;360(9350):2018-2025
23. Frohman E, Phillips T, Kokel K, et al. Disease-modifying therapy in multiple sclerosis: strategies for optimizing management. Neurologist. 2002;8(4):227-236 (Pubitemid 34810404)
24. Daugherty KK, Butler JS, Mattingly M, Ryan M. Factors leading patients to discontinue multiple sclerosis therapies. J Am Pharm Assoc. 2005;45(3):371-375 (Pubitemid 46037299)
25. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;353(5):487-497
26. Costello K, Kennedy P, Scanzillo J. Recognizing nonadherence in patients with multiple sclerosis and maintaining treatment adherence in the long term. Medscape J Med. 2008;10(9):225.
27. McLaughlin J, Zeeberg I. Self-care and multiple sclerosis: a view from two cultures. Soc Sci Med. 1993;37(3):315-329 (Pubitemid 23220550)
28. Gulick EE. Self-assessed health and use of health services. West J Nurs Res. 1991;13(2):195-211; discussion 212-1199
29. Lorig KR, Ritter P, Stewart AL, et al. Chronic disease self-management program: 2-year health status and health care utilization outcomes. Med Care. 2001;39(11):1217-1223 (Pubitemid 33603666)
30. de Ridder D, Geenen R, Kuijer R, van Middendorp H. Psychological adjustment to chronic disease. Lancet. 2008;372(9634):246-255
31. Verbrugge LM. Sex differentials in health. Public Health Rep. 1982;97(5):417-437
32. Bird CE, Rieker PP. Gender matters: an integrated model for understanding men's and women's health. Soc Sci Med. 1999;48(6):745-755
33. Fraser C, Polito S. A comparative study of self-efficacy in men and women with multiple sclerosis. J Neurosci Nurs. 2007;39(2):102-106
34. Schwartz CE, Coulthard-Morris L, Zeng Q, Retzlaff P. Measuring self-efficacy in people with multiple sclerosis: a validation study. Arch Phys Med Rehabil. 1996;77(4):394-398 (Pubitemid 26111758)
35. Minden SL, Frankel D, Hadden L, Perloffp J, Srinath KP, Hoaglin DC. The Sonya Slifka Longitudinal Multiple Sclerosis Study: methods and sample characteristics. Mult Scler. 2006;12(1):24-38. (Pubitemid 43169235)
36. de Leeuw E, Hox J, Dillman D. International Handbook of Survey Methodology. New York: Lawrence Erlbaum Associates; 2008.
37. Miller LG, Liu H, Hays RD, et al. Knowledge of antiretroviral regimen dosing and adherence: a longitudinal study. Clin Infect Dis. 2003;36(4):514-18. (Pubitemid 36241321)
38. Vermeire E, Hearnshaw H, Van Royen P, Denekens J. Patient adherence to treatment: three decades of research. A comprehensive review. J Clin Pharm Ther. 2001;26(5):331-342 (Pubitemid 32989555)
39. Gijsbers van Wijk CM, van Vliet KP, Kolk AM, Everaerd WT. Symptom sensitivity and sex differences in physical morbidity: a review of health surveys in the United States and The Netherlands. Women Health. 1991;17(1):91-124.
40. Steck B, Amsler F, Kappos L, Burgin D. Gender-specific differences coping with chronic somatic disease. Arch Womens Ment Health. 2000;3(1):15-21. (Pubitemid 30434105)
41. Evangelista LS, Kagawa-Singer M, Dracup K. Gender differences in health perceptions and meaning in persons living with heart failure. Heart Lung. 2001;30(3):167-176
42. Fraser C, Hadjimichael O, Vollmer T. Predictors of adherence to Copaxone therapy in individuals with relapsing-remitting multiple sclerosis. J Neurosci Nurs. 2001;33(5):231-239
43. Turner AP, Kivlahan DR, Sloan AP, Haselkorn JK. Predicting ongoing adherence to disease-modifying therapies in multiple sclerosis: utility of the health beliefs model. Mult Scler. 2007;13(9):1146-1152
44. Lublin FD, Whitaker JN, Eidelman BH, Miller AE, Arnason BG, Burks JS. Management of patients receiving interferon beta-1b for multiple sclerosis: report of a consensus conference. Neurology. 1996;46(1):12-18.
45. Cohen JA, Carter JL, Kinkel RP, Schwid SR. Therapy of relapsing multiple sclerosis. Treatment approaches for nonresponders. J Neuroimmunol. 1999;98(1):29-36.
46. Cohen BA. Identification, causation, alleviation, and prevention of complications (ICAP): an approach to symptom and disability management in multiple sclerosis. Neurology. 2008;71(24 Suppl 3):S14-20.
47. Elwyn G, Edwards A, Britten N. What information do patients need about medicines? "Doing prescribing": how doctors can be more effective. BMJ. 2003;327(7419):864-867 (Pubitemid 37271707)
48. Stern D, Reissman D. Specialty pharmacy cost management strategies of private health care payers. J Manag Care Pharm. 2006;12(9):736-744 Available at: http://www.amcp.org/data/jmcp/736-744.pdf. (Pubitemid 47398731)